Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factors Affecting Efficacy and Adverse Reactions of Anlotinib
ChiCTR2500105222Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in bronchial carcinoma, alveolar soft part sarcoma (ASPS), soft tissue sarcoma (STS) and 2 more, sponsored by Changhai Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
bronchial carcinomaalveolar soft part sarcoma (ASPS)soft tissue sarcoma (STS)Medullary Thyroid Cancer (MTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2500105222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105222.